Showing results (101-110 of 111) with videos related to

Sort By:
Pageof 12
Science (New York, N.Y.)|April 9, 2026
Sialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunityJooho Chung, Mounica Vallurupalli, Sarah Noel, et al.
Blood|July 12, 2024
Risk prediction for clonal cytopenia: multicenter real-world evidenceZhuoer Xie, Rami Komrokji, Najla Al Ali, et al.
Blood Reviews|March 18, 2023
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1<sup>st</sup> International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)Jan Philipp Bewersdorf, Zhuoer Xie, Rafael Bejar, et al.
The Lancet. Haematology|December 16, 2019
Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trialAndrew M Brunner, Traci M Blonquist, Daniel J DeAngelo, et al.
Blood Reviews|September 13, 2023
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)Maximilian Stahl, Jan Philipp Bewersdorf, Zhuoer Xie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 9, 2021
Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort StudyVivek Naranbhai, Claire A Pernat, Alexander Gavralidis, et al.
Blood|March 27, 2025
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statementUma Borate, Kelly Pugh, Allyson Waller, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 25, 2024
Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])Fnu Aakash, Savanah D Gisriel, Amer M Zeidan, et al.
Blood Cancer Journal|June 29, 2026
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE databaseJan Philipp Bewersdorf, Tariq Kewan, Luca Lanino, et al.
The Lancet. Haematology|October 11, 2024
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic SyndromesRami S Komrokji, Luca Lanino, Somedeb Ball, et al.
Pageof 12